{
    "clinical_study": {
        "@rank": "156221", 
        "arm_group": [
            {
                "arm_group_label": "CitraFleet", 
                "arm_group_type": "Active Comparator", 
                "description": "Administration of CitraFleet"
            }, 
            {
                "arm_group_label": "MOVIPREP", 
                "arm_group_type": "Experimental", 
                "description": "Administration of MOVIPREP"
            }
        ], 
        "brief_summary": {
            "textblock": "To compare the polyp and adenoma detection rate of MOVIPREP versus an oral Sodium\n      Picosulfate/Magnesium Citrate solution."
        }, 
        "brief_title": "A Multi-centre Study Comparing the Polyp Detection Rate of Two Different Types of Bowel Preparation: a 2-litre Solution (MOVIPREP\u00ae) Versus a Hyperosmotic and Stimulant Combined Low Volume Bowel Preparation (Sodium Picosulfate and Magnesium Citrate)", 
        "completion_date": {
            "#text": "June 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Colorectal Cancer", 
        "condition_browse": {
            "mesh_term": "Colorectal Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patient's written informed consent must be obtained prior to inclusion.\n\n          -  Male or female outpatients or inpatients aged 40 to 80 years with an indication for\n             complete colonoscopy.\n\n          -  Willing to undergo a colonoscopy for diagnostic or surveillance purposes\n\n          -  Patients with a known personal of familial risk of colon neoplasia, willing to\n             undergo a screening colonoscopy\n\n          -  Willing, able and competent to complete the entire procedure and to comply with study\n             instructions.\n\n          -  Females of childbearing potential must employ an adequate method of contraception.\n\n        Exclusion Criteria:\n\n          -  History of gastric emptying disorders.\n\n          -  History of ileus, toxic megacolon, gastrointestinal obstruction and colonic\n             perforation.\n\n          -  History of phenylketonuria.\n\n          -  Known glucose-6-phosphate dehydrogenase deficiency.\n\n          -  Known hypersensitivity to macrogol 3350, sodium sulphate or ascorbic acid/sodium\n             ascorbate.\n\n          -  History of colonic resection.\n\n          -  Requirement for permanent medication and associated stable serum concentrations (e.g.\n             neuroleptic drugs).\n\n          -  Presence of congestive heart failure (NYHA III + IV).\n\n          -  Acute life-threatening cardiovascular disease.\n\n          -  Documented history of severe renal insufficiency (creatinine clearance <30 ml/min).\n\n          -  Other contraindication described in the summary of product characteristics (SmPC) of\n             either preparation.\n\n          -  Patient has a condition, clinically significant laboratory results, or is in a\n             situation which, in the investigator's opinion, may put the patient at significant\n             risk, may confound the study results, or may interfere significantly.\n\n          -  Application of any unlicensed medication within the previous 3 months or\n             participation in any other research study in the last 3 months.\n\n          -  Females who are pregnant, nursing or planning a pregnancy.\n\n          -  Patients who, in the opinion of the investigator, may not be compliant with the study\n             requirements.\n\n          -  Previous participation in this clinical study."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "80 Years", 
            "minimum_age": "40 Years"
        }, 
        "enrollment": {
            "#text": "400", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "September 12, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01689792", 
            "org_study_id": "NOR-01/2011 (PDR)"
        }, 
        "intervention": [
            {
                "arm_group_label": "MOVIPREP", 
                "intervention_name": "MOVIPREP", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "CitraFleet", 
                "intervention_name": "CitraFleet", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Picosulfate sodium", 
                "Magnesium citrate"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "April 8, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Aschaffenburg", 
                    "country": "Germany", 
                    "zip": "Am Hasenkopf 1"
                }, 
                "name": "Klinikum Aschaffenburg"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multi-centre, Randomised, Investigator-blinded Study Comparing the Polyp Detection Rate of Two Different Types of Bowel Preparation: a 2-litre Solution (MOVIPREP\u00ae) Versus a Hyperosmotic and Stimulant Combined Low Volume Bowel Preparation (Sodium Picosulfate and Magnesium Citrate)", 
        "overall_contact": {
            "email": "CBay@norgine.com", 
            "last_name": "Caroline Bay", 
            "phone": "+44 1895 45", 
            "phone_ext": "3689"
        }, 
        "overall_official": {
            "affiliation": "Klinikum Aschaffenburg", 
            "last_name": "Wolfgang Fishbach, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "June 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "Polyp detection rate defined as number of patients with at least one polyp or flat lesion as recorded by the endoscopist", 
            "measure": "Polyp detection rate", 
            "safety_issue": "No", 
            "time_frame": "At colonoscopy"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01689792"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "ADR, (including flat lesions) defined as number of patients with at least one adenoma as recorded by the pathologist in relation to the total analysis population", 
                "measure": "Adenoma Detection Rate (ADR)", 
                "safety_issue": "No", 
                "time_frame": "At the Colonoscopy"
            }, 
            {
                "description": "ADR and PDR by location:\nleft sided (rectum, colon sigmoideum, colon decendens, left half of colon transversum\nright-sided (right half of colon transversum, colon ascendens, caecum", 
                "measure": "ADR and PDR by location", 
                "safety_issue": "No", 
                "time_frame": "at the colonoscopy"
            }, 
            {
                "description": "Cancer detection rate, defined as number of patients with at least one malignancy in relation to the total analysis population", 
                "measure": "Cancer detection rate", 
                "safety_issue": "No", 
                "time_frame": "at the colonoscopy"
            }, 
            {
                "description": "Flat lesion only detection of the patients", 
                "measure": "Flat lesion only detection rate", 
                "safety_issue": "No", 
                "time_frame": "at the colonoscopy"
            }, 
            {
                "description": "Advanced risk lesion detection rate (lesions >1 cm, low grade and/or villous", 
                "measure": "Advanced risk lesion detection rate", 
                "safety_issue": "No", 
                "time_frame": "at the colonoscopy"
            }, 
            {
                "description": "The rate of colonoscopy completion", 
                "measure": "Colonoscopy completion rate", 
                "safety_issue": "No", 
                "time_frame": "at the colonoscopy"
            }, 
            {
                "description": "Colon cleansing quality as reported by the gastroenterologist, according to the Harefield Cleansing Scale\u00a9", 
                "measure": "Colon cleansing quality", 
                "safety_issue": "No", 
                "time_frame": "at the colonoscopy"
            }, 
            {
                "description": "The acceptability and tolerability of the study medication taken by the patients throughout the study using specified patient questionnaires", 
                "measure": "Acceptability and tolerability of medication using patient questionnaires", 
                "safety_issue": "No", 
                "time_frame": "Throughout the study"
            }
        ], 
        "source": "Norgine", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Norgine", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "November 2011", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Investigator), Primary Purpose: Screening", 
        "study_type": "Interventional", 
        "verification_date": "April 2013"
    }
}